Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Regenerative Medical Technology (RMTG) over the last 9 years, with Q3 2025 value amounting to $34.6 million.

  • Regenerative Medical Technology's Total Liabilities rose 1545.23% to $34.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.6 million, marking a year-over-year increase of 1545.23%. This contributed to the annual value of $31.2 million for FY2024, which is 2635.7% up from last year.
  • Per Regenerative Medical Technology's latest filing, its Total Liabilities stood at $34.6 million for Q3 2025, which was up 1545.23% from $33.5 million recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Total Liabilities ranged from a high of $34.6 million in Q3 2025 and a low of $7.4 million during Q1 2021
  • For the 5-year period, Regenerative Medical Technology's Total Liabilities averaged around $23.1 million, with its median value being $23.2 million (2023).
  • Over the last 5 years, Regenerative Medical Technology's Total Liabilities had its largest YoY gain of 14539.59% in 2021, and its largest YoY loss of 3461.3% in 2021.
  • Regenerative Medical Technology's Total Liabilities (Quarter) stood at $16.1 million in 2021, then rose by 24.9% to $20.1 million in 2022, then rose by 22.99% to $24.7 million in 2023, then rose by 26.36% to $31.2 million in 2024, then grew by 10.89% to $34.6 million in 2025.
  • Its last three reported values are $34.6 million in Q3 2025, $33.5 million for Q2 2025, and $32.1 million during Q1 2025.